Zai Lab presented updated Phase 1 data for ZL-1310, an investigational DLL3-targeted antibody-drug conjugate (ADC) for ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Xcelerate has unveiled the bioX Genetics Platform, which cuts the time needed to detect genetic variants by 98% and achieves ...

Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high cancers including colorectal, endometrial, ovarian, and gastric tumors.

The new data from the PERSEUS and CEPHEUS studies show that DARZALEX FASPRO®-based regimens achieve up to 95% 4-year PFS and over 55% sustained MRD negativity in transplant-eligible patients, and 69% ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...

Presented at ASCO 2025, new post-hoc analyses from the Phase III ARANOTE trial showed that darolutamide (Nubeqa) plus ADT extended the time to HRQoL deterioration by 5.1 months and delayed pain ...

The FDA approved darolutamide (Nubeqa®) for metastatic castration-sensitive prostate cancer, based on the Phase III ARANOTE trial, which showed a 46% reduction in radiographic progression or death.

The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death by 40% in relapsed small cell lung cancer (SCLC), extending median overall ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease progression or death by 44% compared to taxane, trastuzumab, and pertuzumab ...